Kobe Healthcare's Analgesic Drug Dilophin Has a 45% Share in the Analgesics

Multiple Choice

Kobe Healthcare's analgesic drug Dilophin has a 45% share in the analgesics market in the country of Bodonia.Its closest competitor,Caritin,has a 25% share in the market,while three other drugs split the remainder.Which statement indicates that Dilophin is a star according to the BCG matrix?

A) Few players are willing to enter the analgesic drug market since the market has poor growth potential.
B) A customer survey has revealed that Dilophin has the poorest brand-name recognition of any analgesic in the market.
C) The demand for analgesic drugs in the Bodonian market is expected to remain stable.
D) Caritin is rapidly gaining market share over Dilophin as a result of aggressive marketing efforts.
E) The Bodonian market for healthcare products is expanding rapidly.